文献速递药物不良反应与药物警戒

化疗后严重不良反应发生率:基于普通癌症登记的研究

Serious adverse effects occurring after chemotherapy: A general cancer registry-based incidence survey.
PubMed 文献 · Br J Clin Pharmacol · 2020-01-16

该研究基于法国某地区普通癌症登记处2012年新发侵袭性癌症患者(除外造血系统肿瘤和皮肤癌),抽取1000例接受新辅助和/或辅助一线化疗的患者,收集严重不良反应并构建药物警戒档案。

要点

  • 拓扑异构酶II抑制剂(依托泊苷、博来霉素)严重不良反应发生率最高(69.2%)
  • 转移灶(53.3%)和合并症(51.3%)与严重不良反应发生率升高相关

核心结论

  • 化疗相关严重不良反应总体发生率较高,应加强药物毒性信息告知并借助患者报告提升认知。

研究设计与样本

  • 基于普通癌症登记处的药物流行病学调查,纳入2012年该地区新发侵袭性癌症患者(除外造血系统肿瘤和皮肤癌),抽取1000例接受新辅助和/或辅助一线化疗(可后续放疗)的患者,收集严重不良反应并构建药物警戒档案。

主要发现

  • 拓扑异构酶II抑制剂(依托泊苷、博来霉素)暴露者严重不良反应发生率为69.2%。
  • 长春花生物碱暴露者严重不良反应发生率为66.7%。
  • 拓扑异构酶I抑制剂暴露者严重不良反应发生率为54.5%,铂类衍生物暴露者为52.0%。
  • 存在转移灶者严重不良反应发生率为53.3%,有合并症者为51.3%,支气管肺癌患者为59.0%。

临床怎么用

  • 临床应针对高发生率方案(如含拓扑异构酶II抑制剂、长春花生物碱、铂类)加强严重不良反应监测与患者教育。
  • 对合并转移灶、合并症及支气管肺癌患者应提高严重不良反应警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pharmaco-epidemiological surveys enable the frequency of serious adverse effects-and also the determining factors of their occurrence and seriousness-to be quantified. Few studies systematically gathering post-chemotherapy adverse effects data have been conducted. The objective was to assess the incidence of post-chemotherapy serious adverse effects on the basis of cancer registry data. METHODS: The population was composed of new invasive cancer cases, with the exception of haematopoietic tumours and cutaneous carcinomas. These cancers were identified in 2012 among patients living at the time of diagnosis in a region covered by a general cancer registry and by a French regional pharmacovigilance centre, and treated with neo-adjuvant and/or adjuvant first-intention chemotherapy, followed or not by radiotherapy. The study was based on a sample of 1000 patients from the registry, followed by the collection of serious adverse effects and the required information to constitute a pharmacovigilance file. RESULTS: Chemotherapy was associated with a particularly high incidence of serious adverse effects, affecting 44.5% (41.4-47.5%) of the patients. The highest incidence rates were observed when patients were exposed to topo-isomerase II inhibitors such as etoposide and bleomycin (69.2%), vinca-alkaloids (66.7%), topo-isomerase I inhibitors (54.5%) and platinum derivatives (52.0%). The clinical context was also linked to incidence, especially in case of metastases (53.3%) and comorbidities (51.3%). Substantial differences were found according to localisation, with a particularly high incidence in bronchial-pulmonary cancers (59.0%). CONCLUSION: The high overall incidence rate of serious adverse effects should motivate a reinforcement of information about drug toxicities and improve knowledge by drawing on patient reporting.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ingrand I, Defossez G, Lafay-Chebassier C, et al. Serious adverse effects occurring after chemotherapy: A general cancer registry-based incidence survey. Br J Clin Pharmacol. 2020. PMID: 31658394. doi:10.1111/bcp.14159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。